Physicians' Academy for Cardiovascular Education

5 Things a cardiologist needs to know about GLP-1RA

This educational video is part of a series called '5 Things a cardiologist needs to know about GLP-1 RA' that are aimed to guide cardiologists in management of patients with type 2 diabetes, since the cardiology practice is increasingly confronted with these patients.

GLP-1RAs: What are the future directions in development?

Subtitling in English, German, Italian, Spanish, French, and Chinese

10' education - Jan. 6, 2021 - Prof. John Deanfield, MD
Prof. Deanfield discusses the changing paradigm for managing cardiometabolic risk in clinical practice by the emergence of diabetes. He states that GLP-1 receptor agonists will be an important component of treatment strategies.

5 Things a cardiologist needs to know about GLP-1 RA Prof. Deanfield discusses the changing paradigm for managing cardiometabolic risk in clinical practice by the emergence of diabetes. He states that GLP-1 receptor agonists will be an important component of treatment strategies.

What is the clinical evidence for the benefits of GLP-1RAs?

*NEW* Subtitling in English, German, Italian, Spanish, French, and Chinese

10' education - Dec. 10, 2020 - Prof. Subodh Verma, MD
Prof. Verma discusses the CV results of clinical trials with GLP-1 RAs and how these translate to CV protection in T2D.

5 Things a cardiologist needs to know about GLP-1RA Prof. Verma discusses the CV results of clinical trials with GLP-1RAs and how these translate to CV protection in T2DM.

Role of GLP-1RA in practice

*NEW* Subtitling in English, German, Italian, Spanish, French, and Chinese

10' education - Dec. 3, 2020 - Prof. Eduard Montanya, MD
First, prof. Montanya describes the US and European recommendations for the use of GLP-1RA in T2DM patients, and then discusses when to intitiate GLP-1RA in patients with high CV risk or clinical ASCVD, CKD, or HF, or in those with low CV risk.

5 Things a cardiologist needs to know about GLP-1RA First, prof. Montanya describes the US and European recommendations for the use of GLP-1RA in T2DM patients, and then discusses when to intitiate GLP-1RA in patients with high CV risk or clinical ASCVD, CKD, or HF, or in those with low CV risk.

How do GLP-1RAs work?

New - subtitling in English, German, Italian, Spanish, French, and Chinese

10' education - Dec. 1, 2020 - Prof. Naveed Sattar, MD
Prof. Sattar describes the mechanism of action of GLP-1RAs and provides potential explanations for the cardiovascular benefit observed with these drugs.

5 Things a cardiologist needs to know about GLP-1RA Prof. Sattar describes the mechanism of action of GLP-1RAs and provides potential explanations for the cardiovascular benefit observed with these drugs.

Which patients to consider for GLP-1RA?

*NEW* Click on video for subtitling in English, German, Italian, Spanish, French, or Chinese.

10' education - Nov. 18, 2020 - Prof. Stephan Jacob, MD
Prof. Jacob discusses the shift in management of diabetes by a glycemic approach towards prevention of CV complications. He describes the evolution of the treatment recommendations in T2DM management.

5 Things a cardiologist needs to know about GLP-1RA Prof. Jacob discusses the shift in management of diabetes by a glycemic approach towards prevention of CV complications. He describes the evolution of the treatment recommendations in T2DM management.

5 Things a cardiologist needs to know about GLP-1RA